AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
|Articles|April 1, 2020
- BioPharm International-04-01-2020
- Volume 33
- Issue 4
Benchtop Centrifuges
General Purpose Pro Centrifuge Series centrifuges by Thermo Fisher Scientific are designed to deliver a regulatory-compliant benchtop separation solution to meet the application needs of scientists working in biopharmaceuticals, academic research, and clinical diagnostic applications.
Advertisement
General Purpose Pro Centrifuge Series centrifuges by Thermo Fisher Scientific are designed to deliver a regulatory-compliant benchtop separation solution to meet the application needs of scientists working in biopharmaceuticals, academic research, and clinical diagnostic applications. The series comes equipped with a full color, glass touchscreen; Fiberlite Carbon Fiber Rotors with Auto-Lock Rotor Exchange functions; ClickSeal Biocontainment Lids; a compact separation solution featuring connectivity-ready technology; and a design that meets global compliance standards.
The device utilizes Thermo Scientific Sorvall, Thermo Scientific Multifuge, and Thermo Scientific Megafuge configurations to configure with rotors to solve a range of application needs.
Articles in this issue
over 6 years ago
Bioreactors Redefine Upstream Productivityover 6 years ago
Critical Knowledge for Preparing Auditsover 6 years ago
Can Vaccine Development Be Safely Accelerated?over 6 years ago
What’s New in Downstream Technologiesover 6 years ago
Chromatography Columnsover 6 years ago
Ensuring Smooth Tech Transfer of Bioprocess Operationsover 6 years ago
Biosimilars Tackle Interchangeability Standardsover 6 years ago
Contamination Control for Cell Therapyover 6 years ago
Packaging Preserves the Cold ChainAdvertisement
Related to this article
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
5